Following a 40% plunge in earnings last quarter and a drop of nearly 60% since last year, earnings at Hi-Tech Pharmacal (HITK) are once again set to plunge next week when earnings are released again. A stock drop of up to 60% appears to be approaching quickly. Ongoing fraud investigations have the potential to further exacerbate this drop in a meaningful way, but as a notably under-followed stock, Wall Street simply isn’t paying attention.